Makary’s tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers and physicians on regulatory decisions.
Source: US Top News and Analysis
Related Posts
This little-known tech name soared on earnings. KeyBanc sees more gains ahead
Zebra Technologies gained 11% in the trading session following its first-quarter earnings, and its shares…
Stocks making the biggest moves midday: Corning, Qualcomm, Wendy’s, Trade Desk & more
Here are the stocks making headlines in midday trading. Source: US Top News and Analysis
Chase Sapphire Reserve launches highest-ever 150,000-point bonus. Here’s how it compares to other cards
The Chase Sapphire Reserve’s new 150,000-point welcome bonus is its highest offer yet. Here’s how…